Fulcrum Therapeutics (FULC) Total Non-Current Liabilities (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Total Non-Current Liabilities data on file, last reported at $13.3 million in Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities fell 4.98% year-over-year to $13.3 million in Q1 2026; TTM through Mar 2026 was $13.3 million, a 4.98% decrease from a year earlier, with the FY2025 full-year figure at $17.1 million, down 2.29% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $13.3 million, down from $17.1 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for FULC reached as high as $34.3 million in Q2 2022 and fell as low as $13.3 million in Q1 2026.
• Historically, Total Non-Current Liabilities has averaged $21.0 million across 5 years, with a median of $20.9 million in 2024.
• Across the five-year window, Total Non-Current Liabilities rose 17.41% in 2022 and slipped 29.63% in 2025, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $27.5 million in 2022, then retreated by 19.03% to $22.3 million in 2023, then dropped by 21.6% to $17.5 million in 2024, then fell by 2.29% to $17.1 million in 2025, then declined by 22.34% to $13.3 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $13.3 million in Q1 2026, $17.1 million in Q4 2025, and $16.3 million in Q3 2025.